Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-cash Items (2021 - 2024)

Historic Non-cash Items for Inhibikase Therapeutics (IKT) over the last 3 years, with Q4 2024 value amounting to $31.1 million.

  • Inhibikase Therapeutics' Non-cash Items changed N/A to $31.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.1 million, marking a year-over-year change of. This contributed to the annual value of $31.1 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Inhibikase Therapeutics reported Non-cash Items of $31.1 million as of Q4 2024.
  • Inhibikase Therapeutics' Non-cash Items' 5-year high stood at $31.1 million during Q4 2024, with a 5-year trough of $300000.0 in Q4 2022.
  • Moreover, its 3-year median value for Non-cash Items was $2.0 million (2021), whereas its average is $11.1 million.
  • Examining YoY changes over the last 5 years, Inhibikase Therapeutics' Non-cash Items showed a top increase of 8500.0% in 2022 and a maximum decrease of 8500.0% in 2022.
  • Quarter analysis of 3 years shows Inhibikase Therapeutics' Non-cash Items stood at $2.0 million in 2021, then tumbled by 85.0% to $300000.0 in 2022, then soared by 10266.67% to $31.1 million in 2024.
  • Its Non-cash Items stands at $31.1 million for Q4 2024, versus $300000.0 for Q4 2022 and $2.0 million for Q4 2021.